clinical outcomes in pts with dose reduction of selinexor in combination with bortezomib, and dex
Published 2 years ago • 294 plays • Length 1:57
Download video MP4
Download video MP3
Similar videos
-
4:35
dose reduction of selinexor in combination with bortezomib and dexamethasone in multiple myeloma
-
6:14
results of iberdomide in combination with dex and daratumumab or bortezomib in patients with rrmm
-
5:00
oral selinexor plus low dose dex in pts with penta exposed and triple class-refractory mm
-
13:22
efficacy and toxicity of selinexor: importance of dose intensity and post progression outcomes
-
6:51
once weekly selinexor, carfilzomib and dexamethasone in triple class refractory multiple myeloma
-
3:52
overall survival with oral selinexor low dose dex in pts with triple class refractory-mm
-
1:03:56
selinexor combinations in clinical trials with dr. jeffrey zonder
-
4:45
iberdomide in combination with dex in pts with rrmm: results from the cc-220-mm-001 trial
-
5:25
selinexor, daratumumab, and dex in pts with mm previously exposed to pis and imids
-
3:11
iberdomide in combination with dex and dara, bort, or cfz in pts with rrmm
-
4:34
weekly svd vs twice weekly vd in pts with mm: initial results of the phase iii boston study
-
10:44
isatuximab plus pomalidomide/low-dose dex vs pomalidomide/low-dose dex in pts with rrmm (icaria-mm)
-
3:50
selinexor: a clear role in heavily pre-treated multiple myeloma
-
11:06
first-in-human phase i study of the novel celmod agent cc-92480 combined with dex in pts with rrmm
-
9:45
selinexor, bortezomib and dexamethasone shows pfs benefit for multiple myeloma
-
2:48
bellini, a phase iii study of venetoclax or placebo in combination with bortezomib and dex in rrmm
-
11:13
isatuximab, carfilzomib, lenalidomide, and dex (isa-krd) in pts with high-risk newly diagnosed mm
-
12:14
once weekly selinexor, carfilzomib, and dexamethasone (xkd) in heavily pretreated multiple myeloma
-
59:40
ongoing myeloma care
Clip.africa.com - Privacy-policy